Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium

Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium

Kineta CSO Thierry Guillaudeux Invited to Participate at the 2nd Annual VISTA Virtual Symposium

Seattle, WA — (September 14, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, has been invited to present at the 2nd Annual VISTA Symposium. The virtual event will take place on September 23, 2022.

“I am excited to join leading immuno-oncology experts in discussing the latest advances in anti-VISTA immunotherapies,” said Dr. Guillaudeux.  “VISTA is an important myeloid checkpoint with a unique mechanism of action bridging innate and adaptive immunity. Anti-VISTA therapies have great potential to improve cancer treatment outcomes in a variety of solid tumors, especially for patients resistant to standard of care therapies including first generation immune checkpoint inhibitors.”

Dr. Guillaudeux will join leading researchers and clinicians in immunology to discuss new insights into VISTA, a promising therapeutic target for cancer.  The symposium will focus on VISTA’s function and applicability in cancer immunology, as well as the latest research and development in programs targeting VISTA.

Presentation Details: 

Session Title:  VISTA Biology
Date:  September 23, 2022
Time:  9:20 AM to 10:00 AM Eastern Time

Session Title:  Anti-VISTA Therapeutic Strategies
Date:  September 23, 2022
Time:  12:10 PM to 12:55 PM Eastern Time

Click on the link below for additional details and to register for the symposium:

https://www.eventbrite.com/e/2nd-annual-vista-symposium-tickets-374510088757

####

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways.  It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND-enabling and clinical studies.

KVA12.1  is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.  It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.  These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.

Anti-CD27 mAb program:  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.

Additional Information and Where to Find It
This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta and between Yumanity and Janssen Pharmaceutica NV (“Janssen”). In connection with the proposed transactions, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 29, 2022 a registration statement on Form S-4 (“the Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 

Participants in the Solicitation
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

 

Source: Kineta, Inc.

Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference

Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference

Kineta Announces Participation in the H.C. Wainwright 24th Annual Global Healthcare Conference

Seattle, WA — (September 12, 2022)  Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.  The conference is being held as a hybrid event on September 12-14, 2022.  The in-person venue for the event is the Lotte New York Palace Hotel in New York City.  Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.

Shawn Iadonato, Ph.D., Kineta’s Chief Executive Officer, will provide a corporate update and overview of KVA12.1, Kineta’s IND-ready VISTA blocking immunotherapy that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022.

Event:  H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
Date:  September 12-14, 2022
Time:  7:00 A.M. Eastern Time
Location:  Virtual webcast to start on-demand on September 12, 2022 at 7:00 A.M. Eastern Time

Participants may access the webcast of the event through the following link:

https://journey.ct.events/view/54d1d52b-9a16-453d-a34a-010235061f02

The webcast can also be accessed in the Investors section of the Kineta website at www.kinetabio.com. The webcast replay will be available shortly after the conclusion of the event for 30 days.

####

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta, please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways.  It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND-enabling and clinical studies.

KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.  It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.  These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.

Anti-CD27 mAb program:  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.

Additional Information and Where to Find It
This press release may be deemed to be solicitation material with respect to the proposed transactions between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta and between Yumanity and Janssen Pharmaceutica NV (“Janssen”). In connection with the proposed transactions, Yumanity filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 29, 2022 a registration statement on Form S-4 (“the Registration Statement”), which contains a preliminary proxy statement and prospectus. The Registration Statement has not yet become effective. Yumanity will mail the definitive proxy statement/prospectus to the Yumanity securityholders, and the securities may not be sold or exchanged until the Registration Statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transactions. This press release is not a substitute for the Registration Statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transactions.

Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This press release shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transactions. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, is set forth in the preliminary proxy statement/prospectus included in the Registration Statement and will be set forth in the definitive proxy statement/prospectus and any other relevant documents to be filed with the SEC. You may obtain free copies of these documents as described above.

Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain forward-looking statements, including, without limitation, statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects; statements regarding the proposed merger between Yumanity and Kineta and the proposed asset sale to Janssen, including whether and when the transactions will be consummated; statements about the structure, timing and completion of the proposed transactions; and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including, without limitation, progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. 

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

Source: Kineta, Inc.

Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer

Kineta Announces Appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer

Seattle, WA — (June 28, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the appointment of Thierry Guillaudeux, PhD to Chief Scientific Officer of the Company.   As Chief Scientific Officer, Dr. Guillaudeux will lead Kineta’s R&D team and oversee all of Kineta’s innovative drug programs from discovery through clinical development.

“Dr. Guillaudeux is a highly regarded immunologist and an exceptional leader, and we are pleased to recognize his contributions to the Company with his promotion to Chief Scientific Officer,” said Shawn Iadonato, PhD, Chief Executive Officer of Kineta.   “Thierry has been the driving force in expanding Kineta’s pipeline of potential best-in-class immuno-oncology products targeting VISTA, CD27 and our newly unveiled CD24 program.”

Dr. Guillaudeux has over 30 years of experience in immuno-oncology research and development in France and the United States.  He joined Kineta in 2019 as SVP, Immuno-oncology and built a world-class research team, expanded Kineta’s proprietary PiiONEER™ platform and advanced the Company’s immuno-oncology pipeline including KVA12.1, a potential best-in-class VISTA blocking immunotherapy.   KVA12.1 will be initiating Phase 1 clinical trial in patients with advanced solid tumors in Q4 2022.  Prior to joining Kineta in 2019, Dr. Guillaudeux built a strong executive background in academia as an Associate Professor at the University of Rennes 1. He also headed a research laboratory at the French National Institute of Health with more than 60 employees and served as a Vice President in Technology Transfer at the University of Rennes.  Dr. Guillaudeux previously served as a board member of Satt ouest valorisation and IRT bcom, two French biotechnology companies .

Dr. Guillaudeux’s fields of expertise are in B cell lymphoma, lung cancer and the tumor microenvironment. He has published over 40 peer-review publications and is a co-inventor of multiple patents.  He received his B.S. and M.S. degrees from the University of Rennes and his PhD in Immuno-oncology from the University of Toulouse. He achieved his post-doctorate at the Fred Hutchinson Cancer Research Center and was responsible for the sequencing of the Human Major Histocompatibility Complex I.

####

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways.  It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND enabling and clinical studies.

KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.  It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.  These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.

Anti-CD27 mAb program:  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.  Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material with respect to the proposed transaction between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta . In connection with the proposed transaction, Yumanity intends to file relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that will contain a prospectus and a proxy statement. Yumanity will mail the proxy statement/prospectus to the Yumanity stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transaction. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transaction. Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. 

Participants in the Solicitation

Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transaction. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, will be set forth in the proxy statement/prospectus, which will be included in Yumanity’s registration statement on Form S-4 when it is filed with the SEC. You may obtain free copies of these documents as described above.

NOTICE: This press release contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns, anticipated drug effects in human subjects and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Contact:

Jacques Bouchy
jbouchy@kineta.us

(206) 378-0400

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

Kineta Presents New Preclinical Data and Phase 1/2 Clinical Trial Design of KVA12.1 at the Tumor Myeloid-Directed Therapies Summit

Seattle, WA — (June 17, 2022)  Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it presented the Phase 1/2 clinical trial design and new preclinical data supporting KVA12.1 as a potential treatment for cancer patients with advanced solid tumors at the Tumor Myeloid-Directed Therapies Summit held on June 14-16 in Boston, MA.

Shaarwari Sridhar, Scientist at Kineta, presented a poster outlining the first-in-human clinical trial design and study objectives evaluating KVA12.1 as a monotherapy and in combination with an anti-PD1 immunotherapy.   New preclinical and toxicology data supporting advancing KVA12.1 into clinical development were also presented.  KVA12.1 is a potential best-in-class VISTA blocking immunotherapy that was discovered through the Company’s proprietary immuno-oncology PiiONEER™ platform.  The Phase 1/2 study will be a multicenter, open label, dose escalation and dose expansion study of intravenous infusion of KVA12.1 as a monotherapy and in combination with a fixed dose of an anti-PD1 antibody in patients with advanced solid tumors.  Kineta plans to initiate the Phase 1/2 clinical study in Q4 2022.

“We are very encouraged by the preclinical data and are excited for KVA12.1 to enter the clinic later this year,” said Thierry Guillaudeux, PhD, EVP Research and Development at Kineta. “KVA12.1 was developed through Kineta’s PiiONEER™ platform as an engineered IgG1 monoclonal antibody that binds to a unique epitope at physiologic and acidic Ph levels.  It is highly differentiated as it has demonstrated efficacy as a single agent and in combination with PD-1 in multiple tumor models with no CRS-associated cytokine secretion seen in preclinical tox studies.”

Phase 1/2 clinical study objectives detailed in the poster presentation include:

  • Clinical
    • Safety measurements and DLTs as single agent and in combination with anti-PD1
    • Overall Response Rate and durability of response using RECISTv1.1
    • Determined MTD and R2PD
  • Pharmacologic and Biomarker
    • PK
    • Receptor Occupancy
    • Cytokine and Chemokine profiles in plasma samples
    • Flow Cytometry for PD marker on Immune cells
    • Tumor biopsies : multiparameter analysis to evaluate tumor cells as well as Immune infiltrating cells. Characterized expression of immune checkpoint and exhausted markers. 

Presentation Details:

Title: KVA12.1 a novel fully human anti-VISTA antibody to treat cancer patients with advanced solid tumors
Date Presented:  June 15-16, 2022
Presenter:  Shaarwari Sridhar

For further details, please view the poster presentation on Kineta’s website here.

####

Kineta is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  Kineta has leveraged its expertise in innate immunity with an intent to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta please visit www.kinetabio.com, and follow Kineta on Twitter, LinkedIn and Facebook.

PiiONEER™ Platform is focused on developing fully human monoclonal antibodies that target novel innate immune pathways.  It was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer immune resistance to current therapies. Utilization of the PiiONEER™ Platform results in novel, well-characterized lead antibody therapeutics that can be efficiently advanced into formal IND enabling and clinical studies.

KVA12.1 is a potential best-in-class VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment.  It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope. KVA12.1 may be an effective immunotherapy for many types of cancer including NSCLC (lung), colorectal, renal cell carcinoma, head and neck, and ovarian.  These initial target indications represent a significant unmet medical need with a large worldwide commercial opportunity for KVA12.1.

Anti-CD27 mAb program:  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.  Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.

Additional Information and Where to Find It
This communication may be deemed to be solicitation material with respect to the proposed transaction between Yumanity Therapeutics, Inc. (“Yumanity”) and Kineta . In connection with the proposed transaction, Yumanity intends to file relevant materials with the U.S. Securities and Exchange Commission (the “SEC”), including a registration statement on Form S-4 that will contain a prospectus and a proxy statement. Yumanity will mail the proxy statement/prospectus to the Yumanity stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective. Investors and securityholders of Yumanity and Kineta are urged to read these materials when they become available because they will contain important information about Yumanity, Kineta and the proposed transaction. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Yumanity may file with the SEC or send to securityholders in connection with the proposed transaction. Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Yumanity’s website at www.yumanity.com, on the SEC’s website at www.sec.gov or by directing a request to Yumanity’s Investor Relations at (212) 213-0006 ext. 331.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation
Each of Yumanity, Kineta and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Yumanity in connection with the proposed transaction. Information about the executive officers and directors of Yumanity is set forth in Yumanity’s Definitive Proxy Statement on Schedule 14A relating to the 2022 Annual Meeting of Stockholders, filed with the SEC on April 25, 2022. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Yumanity, will be set forth in the proxy statement/prospectus, which will be included in Yumanity’s registration statement on Form S-4 when it is filed with the SEC. You may obtain free copies of these documents as described above.

NOTICE: This press release contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns, anticipated drug effects in human subjects and other statements that are not historical in nature. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs and legislative, fiscal and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement. Except as required by law, Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022

Kineta Presenting in Multiple Sessions at the Preclinical Immuno-oncology Online 2022

Seattle, WA — (May 18, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today its participation at Preclinical Immuno-oncology Online 2022.  Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, will make a presentation on “Human Knock-In Mice For Selecting Next Generation Immune Checkpoint Inhibitors” and participate in a panel discussion on “The Future of In Vivo Models” at the virtual symposium to be held on May 18, 2022.

As part of his presentation, Dr Guillaudeux will discuss key technology and advantages of Kineta’s proprietary PiiONEER™ platform.  The company’s immuno-oncology platform was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer resistance to current therapies.  Kineta has developed novel, innate immuno-oncology antibody therapeutics targeting VISTA and CD27.

“I am thrilled to participate in this symposium and discuss Kineta’s immuno-oncology focused PiiONEER™ platform”, said Dr. Guillaudeux.  “Kineta’s specialized in vivo preclinical models are used to characterize a therapeutic antibody’s anti-cancer efficacy, pharmacokinetics, receptor occupancy and biomarkers and are key development technologies in our innovative platform”

Kineta has developed monoclonal antibody programs targeting VISTA and CD27 through the PiiONEER™ platform.  KVA12.1 is a potential best-in-class VISTA blocking immunotherapy.  It is a fully human engineered IgG1 monoclonal antibody that was designed to bind to VISTA through a unique epitope.  In preclinical models, KVA12.1 demonstrates strong single agent efficacy in cold tumors and complementary efficacy when dosed in combination with other checkpoint inhibitors (CPI’s).  It is well-tolerated with no change IL6 and TNFα levels responsible for cytokine release syndrome (CRS) in preclinical toxicology studies.  KVA12.1 is being developed as an intravenous infusion for patients with advanced solid tumors. Kineta plans to initiate Phase 1 clinical studies in Q4 2022.  Kineta is also developing an anti-CD27 agonist monoclonal antibody for patients with solid and hematologic tumors.  Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.

Preclinical Immuno-oncology Online 2022 is a virtual conference that assembles a wide range of senior leaders from leading healthcare, biotech, pharma and research institutions.  The conference delves into the challenges and opportunities in innovative approaches to preclinical drug development with a goal to achieve translational success.

Presentation Details

Title:   The Future Of In Vivo Models
Presenter:  Thierry Guillaudeux, PhD
Session Type: Panel discussion
Session Time:  May 18, 2022  7:40AM – 8:10AM  Pacific Time

Title:   Human Knock-In Mice For Selecting Next Generation Immune Checkpoint Inhibitors
Presenter:  Thierry Guillaudeux, PhD
Session Type: Virtual presentation
Session Time:  May 18, 2022  8:30AM – 9:00AM  Pacific Time

####

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022

Kineta Unveils New Preclinical Data on its Anti-CD27 Agonist Lead Antibodies at AACR 2022

Seattle, WA — (April 13, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of preclinical data on the company’s anti-CD27 agonist lead antibodies at the American Association for Cancer Research (AACR) Annual Meeting 2022.  Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, presented the company’s poster unveiling new preclinical data.  Kineta is developing fully human anti-CD27 agonist antibodies for the treatment of blood cancers and solid tumors.

“Kineta’s anti-CD27 program was developed through our innate immunity expertise and the company’s proprietary PiiONEER™ platform.   We have confirmed very exciting data with our lead anti-CD27 antibodies demonstrating their activity in inducing T cells as well as NK cell activation” said Dr. Guillaudeux.  “We are encouraged with these preclinical data and believe that CD27 is an important immuno-oncology target for treating cancer patients with its capability of influencing both the innate and adaptive antitumor immune response.”

Key results from the AACR poster presentation:

  • Evaluated 3 lead therapeutic antibodies from our library of 147 fully human anti-CD27 monoclonal antibodies generated in Trianni® mice.
  • Confirmed lead antibodies’ binding potency and cross-reactivity with non-human primate CD27 but not with the murine CD27.
  • Lead candidates demonstrate strong agonist proprieties. They induce NK cell activation as well as T cell proliferation and activation after engagement of NFκ
  • Lead antibodies will be evaluated as a single agent or in combination with other immuno-therapies in vivo in solid and hematological mouse tumor models in hCD27-KI mice.

Click on the link below to access the poster
CD27 Publications – Poster Presentation at ESMO 2022

Presentation Details

Title:   CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number:   5588
Presenter:  Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title:  Therapeutic Antibodies 3
Session Time:  April 13, 2022  9:00AM – 12:30PM  Central Time
Location:  Poster Section 39

####

Anti-CD27 mAb program:  Kineta has developed a diverse set of anti-CD27 agonist antibodies. They are fully human monoclonal antibodies (mAbs) that demonstrate low nanomolar (nM) binding affinity to CD27 in humans. In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.  Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in Q2 2022.

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:

Jacques Bouchy

jbouchy@kineta.us

(206) 378-0400

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022

Kineta to Present Poster on Anti-CD27 Agonist Antibody Program at the AACR Annual Meeting 2022

Seattle, WA — (March 21, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that it will present a poster on the company’s anti-CD27 agonist antibody program at the American Association for Cancer Research Annual Meeting 2022, taking place April 8-13, 2022 onsite in New Orleans, LA and online.  Thierry Guillaudeux, PhD, EVP Research and Development at Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of blood cancers and solid tumors.

Presentation Details

Title:   CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Abstract Number:   5588
Presenter:  Thierry Guillaudeux, PhD
Session Type: In-Person and e-Poster Presentation
Session Title:  Therapeutic Antibodies 3
Session Time:  April 13, 2022  9:00AM – 12:30PM  Central Time
Location:  Poster Section 39

####

CD27 is a clinically validated drug target. It is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a co-stimulatory signal together with its ligand CD70.  CD27 is highly expressed on naïve T cells and also provides a co-stimulatory signal for NK cell activation.  Kineta has developed a diverse set of anti-CD27 agonist antibodies.  They are fully human monoclonal antibodies (mAbs) that demonstrate low nM binding affinity to CD27 in humans.  In preclinical studies, Kineta’s selected lead anti-CD27 agonist mAbs induce T cell proliferation, NK activation and secretion of cytokines involved in T cell priming and recruitment, demonstrating the ability to potentiate new anti-tumor responses.  Kineta is in the final stage of lead selection and plans to nominate a clinical candidate in mid-2022.

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.


NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference

Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference

Kineta Invited to Participate in the Cowen 42nd Annual Health Care Virtual Conference

Seattle, WA — (February 24, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that the company will participate in Cowen’s 42nd Annual Health Care Conference which is taking place virtually on March 7 – 9, 2022.  Members of Kineta’s management team will be available for one-on-one meetings during the conference. The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care industry.

####

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.

 

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Contact:

Jacques Bouchy

jbouchy@kineta.us
(206) 378-0400

Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology Summit

Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology Summit

Kineta to Present on the Company’s PiiONEER™ Platform at the 6th Annual Tumor Models for Immuno-oncology Summit

Seattle, WA — (January 24, 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today an upcoming presentation at the 6th Tumor Models for Immuno-Oncology Summit 2022.  Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, will be presenting an overview of the company’s proprietary PiiONEER™ Platform and the use of human knock-in models for selecting next generation immunotherapies.

Kineta’s immuno-oncology PiiONEER™ Platform was designed for the discovery and development of first or best-in-class immunotherapies that address the major challenges with cancer resistance to current therapies. Utilization of the innate immunity focused PiiONEER™ Platform has resulted in the development of novel, well characterized fully human antibody therapeutics that are being advanced into formal IND enabling and clinical studies.

“We have developed a world-class innate immunity-focused platform for developing important new immunotherapies to treat patients with cancer” said Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta. “A core component of our PiiONEER™ Platform is our in vivo knock in models which are the foundation for the development of our novel VISTA and CD27 antibody programs.”

Presentation Details:
Title: Use of Human Knock-in Models for Selecting New Generation of Immune Checkpoint Inhibitors
Date:  January 26, 7:30AM Pacific Time
Presenter:  Thierry Guillaudeux, PhD

####

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.


NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contact:

Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference

Kineta to Present at the H.C. Wainwright Bioconnect Virtual Conference

Seattle, WA — (January 11 , 2022) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today Kineta’s management team has been invited to participate at H.C. Wainwright Bioconnect Virtual Conference that is being held on January 10-13, 2022.  Shawn Iadonato, Kineta Chief Executive Officer, will present a corporate overview that will be available on-demand from January 10-13 to attendees registering via H.C. Wainwright at https://hcwevents.com/bioconnect/.

####

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies that transform patients’ lives.  We have leveraged our expertise in innate immunity to develop first or best-in-class immunotherapies that address the major challenges with current cancer therapy.  For more information on Kineta visit our website, www.kinetabio.com, and follow us on Twitter, LinkedIn and Facebook.


NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s business which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Kineta undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

 

Contact:
Jacques Bouchy
jbouchy@kineta.us
(206) 378-0400